中文摘要：本发明公开了一种由蕈状支原体亚种、卡普里蛋白和编码多聚核苷酸组成的免疫原蛋白及其制备方法，以及该蛋白在预防蕈状支原体亚种感染方面的应用。该免疫原蛋白可用于降低支原体疫病爆发对人类及动物健康的威胁，并可作为一种安全有效的亚单位疫苗减轻病原感染的持续时间。
 
外文摘要：Immunogenic proteins comprising Mycoplasma mycoides subsp. mycoides and M. mycoides subsp. capri proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to prevent M. mycoides subsp. mycoides infections are disclosed.
NOVELTY - An immunogenic protein chosen from (a) a fusion protein comprising two or more Mycoplasma mycoides proteins chosen from M.mycoides subsp. mycoides (Mmm) and M.mycoides subsp. capri (Mmc) proteins, (b) an Mmm or Mmc protein or fusion protein conjugated with an immunogenic carrier, (c) variants of the proteins of (a) and (b), or (d) a protein corresponding to (a) or (b) from another Mycoplasma strain, species or subspecies, is new.
USE - The immunogenic protein is useful in a composition for treating or preventing a Mycoplasma infection in a vertebrate subject. The subject is a bovine subject. The Mycoplasma infection is contagious bovine pleuropneumonia (all claimed). The immunogenic protein is useful in subunit vaccine for stimulating humoral, cellular and/or protective  immune responses in animals and humans. The Mycoplasma infections in animals are chosen from mastitis, arthritis, otitis, keratoconjunctivitis, synovitis, and reproductive disorders, and in humans are chosen from pneumonia and other respiratory problems such as tracheobronchitis, bronchiolitis, pharyngitis and croup, pelvic inflammatory disease, and cancer. The ability of the immunogenic protein to reduce lung pathology was testing in 10 cattle. The result showed that the immunogenic protein exhibited a protection rate of 84.9%. 
ADVANTAGE - The immunogenic proteins reduce the prevalence of Mycoplasma diseases which lead to life threatening infections in humans and non-human animals and provide safe and effective subunit vaccines, and induce long lasting immunity which quickly responds upon exposure to one or more infectious antigens.
主权项： (1) a composition comprising at least two immunogenic Mmm and/or Mmc proteins chosen from Mmm and Mmc proteins provided in tables 1 and 4 of the patent specification or their immunogenic fragments or variants, or the corresponding Mycoplasma proteins from another Mycoplasma strain, species or subspecies, and an excipient; (2) a DNA molecule modified for expression in Escherichia coli chosen from one of 14 (108-2265) base pair sequences (SEQ ID NOs: 1-27, only odd numbers) all fully defined in the specification, or a DNA sequence that comprises a nucleotide sequence encoding an Mmm protein, where the DNA sequence is present in one of 16 (1608-5046) base pair sequences (SEQ ID NO: 50-80, only even numbers) all fully defined in the specification; (3) a recombinant vector comprising (a) one or more above-mentioned DNA molecules, and (b) control elements that are operably linked to the molecule by a coding sequence in  the molecule and can be transcribed and translated in a host cell; (4) a host cell transformed with the recombinant vector; and (5) method for producing a Mycoplasma protein.
申请号：WO2016CA50864
公开/公告号：WO2017011919A1
申请日：2016-07-22
公开/公告日：2017-01-26
申请/专利权人：UNIV SASKATCHEWAN [CA]; KENYA AGRICULTURE AND LIVESTOCK RES ORGANIZATION (KALRO) [KE]; INT LIVESTOCK RES INST (ILRI) [KE]
发明/设计人：POTTER ANDREW [CA]; GERDTS VOLKER [CA]; PEREZ-CASAL JOSE [CA]; WANG YEJUN [CA]; WESONGA HEZRON [KE]; SOI REUBEN [KE]; NAESSENS JAN [KE]; JORES JOERG [KE]
分类号：A61K39/02; A61K39/385; A61P31/04; A61P37/04; C07K14/30; C07K19/00; C12N15/31; C12N15/62; C12N15/63; C12N15/70
主分类号：A61K39/02; C07K14/30; C12P21/02; C07K2319/00
法律状态：公开发明
点击下载：一种支原体疫苗及其应用